Freudenberg Medical has launched a new hemostasis valve range which has been designed for medical device companies looking to accelerate time to market.
The new hemostasis valve family adds the HyperSeal and CertuSeal valves to the existing FlexSeal valve launched last year. Hemostasis valves are used to minimise blood loss and can facilitate minimally invasive, catheter-based medical procedures. Also being introduced is the new HyperSeal Introducer Sheath with Hydrophilic Coating which joins the FlexSeal Introducer Sheath as a white label device solution for large bore procedures.
Introduced at the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Colorado, these hemostasis valves can be incorporated into therapeutic catheter development projects in order to provide new design options, shorten development time, and lower costs, according to Freudenberg.
“Freudenberg Medical’s hemostasis valves provide a wide range of innovative features designed to greatly improve hemostasis and procedural performance when integrated into next generation catheters and delivery systems,” said Bernie Kaeferlein, director of portfolio management at Freudenberg Medical.
“As a partner for innovation, we are committed to proactively addressing unmet clinical needs and offering our medical device customers a growing portfolio of finished device, design, and process solutions to help improve efficiency and accelerate their time to market.”
